753 related articles for article (PubMed ID: 17617419)
1. A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay.
Kim GG; Donnenberg VS; Donnenberg AD; Gooding W; Whiteside TL
J Immunol Methods; 2007 Aug; 325(1-2):51-66. PubMed ID: 17617419
[TBL] [Abstract][Full Text] [Related]
2. A novel telomerase-based approach to detect natural cell-mediated cytotoxic activity against tumor cells in vitro.
Faraoni I; Cottarelli A; Giuliani A; Bonmassar L; Rossi L; Bonmassar E
J Immunol Methods; 2005 Oct; 305(2):162-72. PubMed ID: 16165149
[TBL] [Abstract][Full Text] [Related]
3. An improved flow cytometry-based natural killer cytotoxicity assay involving calcein AM staining of effector cells.
Jang YY; Cho D; Kim SK; Shin DJ; Park MH; Lee JJ; Shin MG; Shin JH; Suh SP; Ryang DW
Ann Clin Lab Sci; 2012; 42(1):42-9. PubMed ID: 22371909
[TBL] [Abstract][Full Text] [Related]
4. Measurement of NK activity by the microcytotoxicity assay (MCA): a new application for an old assay.
Wahlberg BJ; Burholt DR; Kornblith P; Richards TJ; Bruffsky A; Herberman RB; Vujanovic NL
J Immunol Methods; 2001 Jul; 253(1-2):69-81. PubMed ID: 11384670
[TBL] [Abstract][Full Text] [Related]
5. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
Hermann GG; Zeuthen J; Claësson MH
Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
[TBL] [Abstract][Full Text] [Related]
6. Target-induced natural killer cell loss as a measure of NK cell responses.
Warren H
Curr Protoc Immunol; 2012 Apr; Chapter 14():Unit 14.29.1-15. PubMed ID: 22470134
[TBL] [Abstract][Full Text] [Related]
7. Human cytotoxic effector cells: definition and analysis of activity.
Ortaldo JR
Allergol Immunopathol (Madr); 1991; 19(4):145-56. PubMed ID: 1726345
[TBL] [Abstract][Full Text] [Related]
8. Selective reduction of natural killer cells and T cells expressing inhibitory receptors for MHC class I in the livers of patients with hepatic malignancy.
Norris S; Doherty DG; Curry M; McEntee G; Traynor O; Hegarty JE; O'Farrelly C
Cancer Immunol Immunother; 2003 Jan; 52(1):53-8. PubMed ID: 12536240
[TBL] [Abstract][Full Text] [Related]
9. A novel five-colour flow cytometric assay to determine NK cell cytotoxicity against neuroblastoma and other adherent tumour cells.
Klöss S; Bochennek K; Huenecke S; Zimmermann SY; Kuçi S; Müller T; Wels WS; Klingebiel T; Esser R; Koehl U
J Immunol Methods; 2007 Aug; 325(1-2):140-7. PubMed ID: 17663991
[TBL] [Abstract][Full Text] [Related]
10. Correlation of human CD56+ cell cytotoxicity and IFN-gamma production.
Derby EG; Reddy V; Nelson EL; Kopp WC; Baseler MW; Dawson JR; Malyguine AM
Cytokine; 2001 Jan; 13(2):85-90. PubMed ID: 11145847
[TBL] [Abstract][Full Text] [Related]
11. A novel method for the simultaneous assessment of natural killer cell conjugate formation and cytotoxicity at the single-cell level by multi-parameter flow cytometry.
Godoy-Ramirez K; Franck K; Gaines H
J Immunol Methods; 2000 May; 239(1-2):35-44. PubMed ID: 10821945
[TBL] [Abstract][Full Text] [Related]
12. In vitro responsiveness to interleukins and theophylline of CD16+, CD56- natural killer cells in a patient with chronic granular lymphocyte disorder.
Bayle C; Vitté-Mony I; Lang P; Pico J; Hercend T; Bertoglio J
Leukemia; 1992 May; 6(5):470-6. PubMed ID: 1375700
[TBL] [Abstract][Full Text] [Related]
13. Lymphokine-activated killer cell and natural killer cell activities in patients with systemic sclerosis.
Kantor TV; Whiteside TL; Friberg D; Buckingham RB; Medsger TA
Arthritis Rheum; 1992 Jun; 35(6):694-9. PubMed ID: 1376124
[TBL] [Abstract][Full Text] [Related]
14. A novel cytolysis assay using fluorescent labeling and quantitative fluorescent scanning technology.
Roden MM; Lee KH; Panelli MC; Marincola FM
J Immunol Methods; 1999 Jun; 226(1-2):29-41. PubMed ID: 10410969
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma.
Finke JH; Rayman P; Alexander J; Edinger M; Tubbs RR; Connelly R; Pontes E; Bukowski R
Cancer Res; 1990 Apr; 50(8):2363-70. PubMed ID: 2107973
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometric assay for the simultaneous analysis of cell-mediated cytotoxicity and effector cell phenotype.
Derby E; Reddy V; Baseler M; Malyguine A
Biotechniques; 2001 Sep; 31(3):660, 664-5. PubMed ID: 11570508
[No Abstract] [Full Text] [Related]
17. Synergistic action of a plant rhamnogalacturonan enhancing antitumor cytotoxicity of human natural killer and lymphokine-activated killer cells: chemical specificity of target cell recognition.
Mueller EA; Anderer FA
Cancer Res; 1990 Jun; 50(12):3646-51. PubMed ID: 1692765
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of superior anti-tumor cytotoxic response of interleukin 15-induced lymphokine-activated killer cells.
Ozdemir O; Ravindranath Y; Savaşan S
J Immunother; 2005; 28(1):44-52. PubMed ID: 15614044
[TBL] [Abstract][Full Text] [Related]
19. Assessment of human natural killer and lymphokine-activated killer cell cytotoxicity against Toxoplasma gondii trophozoites and brain cysts.
Dannemann BR; Morris VA; Araujo FG; Remington JS
J Immunol; 1989 Oct; 143(8):2684-91. PubMed ID: 2477453
[TBL] [Abstract][Full Text] [Related]
20. Single-colour flow cytometric assay to determine NK cell-mediated cytotoxicity and viability against non-adherent human tumor cells.
Thakur A; Zaman A; Hummel J; Jones K; Hortelano G
Biotechnol Lett; 2012 Mar; 34(3):447-53. PubMed ID: 22187077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]